AAREY DRUGS PHARMACEUTICALS LTD Q1 RESULTS
Expert panel to soon weigh plan to use generics for prescription drugs
An expert committee is set to discuss the feasibility of allowing generic substitutions for prescription drugs in India. The proposal has sparked a disagreement between the Indian Pharmaceutical Alliance (IPA) and the All India Drug Action Network (AIDAN). The IPA opposes the idea, arguing that it would lead to a surge of demand from trade channels, such as general pharmacy stores, which would not benefit patients.
Wockhardt Q4 Results: Company posts consolidated net loss of Rs 177 crore
Drug firm Wockhardt on Tuesday reported a consolidated net loss of Rs 177 crore for the fourth quarter ended March 31, 2024. The company had reported a net loss of Rs 237 crore in the January-March quarter of 2022-23.
Torrent Pharma, Glenmark Pharma shares jump up to 9% after Q4 results
Shares of Torrent Pharma and Glenmark Pharma surged post Q4 results. Torrent Pharma's net profit jumped 56% YoY while Glenmark Pharma reported increased losses. Motilal Oswal provides target prices for both companies.
Torrent Pharma Q4 Results: Net profit jumps 56% YoY to Rs 449 crore
Torrent Pharmaceuticals Ltd on Friday reported a 56.45 per cent jump in consolidated net profit to Rs 449 crore in the March quarter, riding on higher revenue.
Torrent Pharma board approves to raise Rs 5,000 crore
Torrent Pharmaceuticals, actively seeking to expand through acquisitions, has expressed interest in purchasing Mumbai-based pharmaceutical company JB Pharma, according to a report by ET on Friday.
Biocon inks licensing, supply pact with South Korea's Handok for chronic weight management product
Biocon signs exclusive licensing agreement with Handok for commercialisation of synthetic Liraglutide in South Korea, expanding portfolio to address weight management needs and tapping into a USD 47 million market opportunity. Biocon said the total addressable market opportunity of Liraglutide in South Korea is approximately USD 47 million as per the IQVIA MAT Q4 2023.
- Go To Page 1
Sun Pharma shares tumble 5% but brokerages raise target up to Rs 1,785. Should you buy, sell or hold?
In Thursday's trading session on the BSE, shares of Sun Pharmaceutical Industries declined by 5%, reaching the day's low of Rs 1,467. This drop occurred despite the company reporting a 34% year-on-year (YoY) increase in its Q4 profit to Rs 2,654.6 crore, with revenue rising by 10.1% YoY to Rs. 11,813 crore in Q4FY24.
Gland Pharma Q4 Results: Net profit more than doubles to Rs 192.4 crore
The company declared its first-ever post-listing dividend of Rs 20 per equity share for FY24.
Sun Pharma net profit jumps 34% YoY to Rs 2,654.6 crore in Q4FY24
Sun Pharma's Q4FY24 net profit rises 34% YoY to Rs 2654.6 crore, driven by increased sales of global specialty products. Interim dividend of Rs. 5 declared for FY24.
Eris Lifesciences Q4 Results: Net profit jumps over 29% to Rs 80 crore
The Ahmedabad-based drug maker reported a net profit of Rs 61.5 crore during the corresponding quarter of the previous year. Revenue of Q4FY 24 grew by 37% YoY to Rs 551 crore. The net debt on March 31 stood at Rs 2700 crore.
Zydus Lifesciences Q4 Results: Drug makers posts threefold YoY jump in net profit to Rs 1,182 crore
Zydus Lifesciences on Friday reported Rs 1,182 crore net profit in Q4FY24, a threefold year-on-year (YoY) jump led by growth in US, India, Europe and emerging market sales.
Zydus Q4 Results: Net profit surges 4-fold to Rs 1,182 crore; revenue at Rs 5,534 cr
Zydus Lifesciences on Friday said its consolidated net profit surged four-fold to Rs 1,182 crore for the fourth quarter ended March 31, 2024 on higher sales. The drug firm had reported a net profit of Rs 297 crore in the January-March quarter of the 2022-23 fiscal.
Mankind Pharma Q4 Results: Net profit jumps 62% YoY to Rs 477 crore
Mankind Pharma on Wednesday reported 62% year-on-year (YoY) jump in net profit to Rs 477 crore in Q4FY24 led by strong domestic formulation sales and one-off US export opportunities.
Heatwave ignites surge in chronic therapy demand
Rising temperatures across various regions of India are driving increased demand for medications aimed at managing chronic conditions. This includes prescriptions for high blood pressure (antihypertensives), cholesterol (lipid-lowering drugs), and blood clotting (platelet aggregation inhibitors).
Alembic Pharma Q4 Results: Posts higher profit on strong N.America sales
Alembic Pharma Q4 Results: Indian generic drugmaker Alembic Pharma reported a 17% rise in fourth-quarter profit on Thursday, driven by strong sales, especially in the key North American market.
Dr Reddy's Labs Q4 Results: PAT jumps 36% YoY to Rs 1,307 crore; firm declares dividend of Rs 40/share
Dr Reddy's Labs Q4 Results: The revenue from operations rose 12% YoY to Rs 7,083 crore while they dipped 2% quarter-on-quarter (QoQ). The revenue missed ET Now poll estimate of Rs 7,237 crore.
Dr Reddy's Q4 Results: Net profit jumps 36% YoY to Rs 1307 crore
Dr Reddy's has reported a 36% year-on-year jump in quarterly net profit, helped by increase in volumes of base business, new product launches, partially offset by price erosion in certain markets.
Lupin share price drops 5% post Q4 earnings
Lupin Share Price: Its revenue from operations in the same period jumped 12% YoY to Rs 4,961 crore as against Rs 4430 crore in the corresponding period of last year.
Lupin Q4 Results: Profit jumps 52% YoY to Rs 368 crore; revenue up 12%
Lupin reported a 52% YoY growth in net profit to Rs 368 crore for March 2024 quarter. Revenue increased by 12% to Rs 4,961 crore. The company declared a dividend of Rs 8 per share.
Q4 results today: Titan, Britannia, Adani Green among 49 companies to announce earnings on Friday
Q4 results today: 49 companies, including Titan and Adani Green, to reveal Q4 results. Titan foresees 18% revenue growth and 13% net profit rise. Watch out for updates from Titan, Britannia, MRF, Tata Tech, and other key players.
Ajanta Pharma shares jump over 13% on strong Q4 results, buyback plans
Ajanta Pharma shares jumped 13% to Rs 2,532 in Friday's trade on BSE after the firm's consolidated net profit increased 66% year-on-year (YoY) to Rs 203 crore in the March quarter, aided by robust sales across domestic and international markets. The drug maker had reported a net profit of Rs 122 crore in the January-March quarter of the previous fiscal.
Ajanta Pharma Q4 Results: Net profit soars 66% YoY to Rs 203 cr
Revenue from operations rose to Rs 1,054 crore in the fourth quarter of FY24 as compared with Rs 882 crore in the year-ago period, Ajanta Pharma said in a regulatory filing. For the year ended March 31, 2024, the company posted a consolidated net profit of Rs 816 crore as against Rs 588 crore in the 2022-23 fiscal year.
GE HealthCare Q1 Results: Co misses quarterly revenue estimates on weakness in China market
GE HealthCare Technologies missed first-quarter revenue estimates on Tuesday, hurt by lower sales in China market and weaker-than-expected demand for its scanning devices, sending its shares tumbling as much as 12% before the bell.
Q4 results this week: Adani group to lead as 211 companies will declare earnings
With 211 companies announcing quarterly results this week, investors are particularly watching out for major names like Kotak Mahindra Bank, DMart, Ultratech Cement, Indian Oil, and many others across various industries.
Dr Reddy’s, Sun, Cipla and Biocon look to recreate Ozempic magic in India
Doctors say patients come with specific queries regarding weight-loss drugs, which have become both the first preference and the last resort for some. “I would rather go for these short cuts that the pharma industry offers than go under the knife for my appearance,” says Rajput. The drugs — Wegovy and Ozempic — which have the same ingredient, semaglutide, are all the rage ever since entrepreneur Elon Musk tweeted about it.
Q4 preview: 6 companies likely to report doubling of sales. Do you own any?
6 companies expected to double sales in Q4 with sectors like automobiles, banks, gas utilities, pharmaceuticals showing YoY sales growth. Sunteck Realty set for a significant jump in net sales.
Glenmark Q3 Results: Co reports net loss of Rs 351 cr on lower domestic sales
Total revenue from operations declined to Rs 2,507 crore as compared with Rs 3,100 crore in the year-ago period, Glenmark Pharma said in a statement.
Sun Pharma's steady Q3 earnings prompt target upgrades by brokerages. Should you buy?
The stock was trading with minor gains at the opening time and hit the day's high of Rs 1,430.45 on the NSE, up 0.84% over the Wednesday closing price.
Sun Pharma Q3 Results: Cons PAT rises 17% YoY to Rs 2,561 crore; Rs 8.5/sh dividend announced
Sun Pharmaceutical Industries reported a 17.4% YoY growth in net profit for Q4, beating estimates. Consolidated revenue grew 10% YoY. The company recommended an interim dividend payout. EBITDA rose 16% YoY and margins expanded. Raw material cost fell, but staff cost increased. India formulation sales and US formulation sales grew, while emerging markets formulation sales declined.
Load More
